The estimated Net Worth of Niamh Louise Pellegrini is at least $5.94 Milion dollars as of 10 March 2021. Ms. Pellegrini owns over 750 units of Nevro Corp stock worth over $188,249 and over the last 10 years she sold NVRO stock worth over $718,408. In addition, she makes $5,037,790 as Chief Commercial Officer at Nevro Corp.
Niamh has made over 10 trades of the Nevro Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 750 units of NVRO stock worth $48,713 on 10 March 2021.
The largest trade she's ever made was selling 1,817 units of Nevro Corp stock on 22 October 2020 worth over $299,805. On average, Niamh trades about 364 units every 8 days since 2014. As of 10 March 2021 she still owns at least 39,968 units of Nevro Corp stock.
You can see the complete history of Ms. Pellegrini stock trades at the bottom of the page.
Niamh Louise Pellegrini serves as Chief Commercial Officer of the Company. From September 2018 to June 2019, Ms. Pellegrini was Vice President of Global Commercial Operations for Abbott Vascular. From April 2016 to September 2018, Ms. Pellegrini served as CEO and President at Autonomic Technologies, Inc. From October 2014 to October 2015, Ms. Pellegrini was President, North America at Thoratec Corporation. Prior to joining Thoratec Corporation, Ms. Pellegrini served in progressively responsible global business development, strategy and commercial roles at Johnson & Johnson. Ms. Pellegrini graduated from Santa Clara University with an M.B.A and a B.S. in finance.
As the Chief Commercial Officer of Nevro Corp, the total compensation of Niamh Pellegrini at Nevro Corp is $5,037,790. There are 1 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.
Niamh Pellegrini is 53, she's been the Chief Commercial Officer of Nevro Corp since 2019. There are 20 older and 4 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
Niamh's mailing address filed with the SEC is C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD, CA, 92008.
Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo oraz & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
Nevro Corp executives and other stock owners filed with the SEC include: